ISPCHealthcare · Diagnostics & ResearchISPC Stock Forecast: iSpecimen, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 1 Aug 2026 — in the lower half.
ISPC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores iSpecimen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own iSpecimen, Inc. — and when they’d sell — is the membership.
ISPC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ISPC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2022 | EF Hutton | Maintains | Buy | $5.50 → $4.25 |
| 4 Jan 2022 | Craig-Hallum | Initiates | Buy | — |
| 22 Nov 2021 | EF Hutton | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ISPC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
iSpecimen, Inc. (ISPC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.0×
- Price / sales
- 2.6×
- Price / book
- 1.7×
- EV / EBITDA
- −0.0×
Cheaper than 75% of US stocks
Cheaper than 45% of US stocks
Cheaper than 50% of US stocks
Cheaper than 62% of US stocks
- Revenue growth (YoY)
- −85.2%
- Earnings growth (YoY)
- −85.2%
- Gross margin
- 45.9%
- Operating margin
- −1627.1%
- Net margin
- 1.2%
Higher than 3% of US stocks
Higher than 4% of US stocks
Higher than 59% of US stocks
Higher than 5% of US stocks
Higher than 50% of US stocks
- Return on equity
- −894.6%
- Return on assets
- −91.8%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ISPC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ISPC appears on the weeks it earns a place.
Frequently asked questions about ISPC stock
Is ISPC stock a buy right now?
Of the 1 analysts covering iSpecimen, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks iSpecimen, Inc. 26 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ISPC?
As at 1 Aug 2026, iSpecimen, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
What is the ISPC stock forecast for 2030?
No analyst covering iSpecimen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ISPC are extrapolating price history, which says nothing about the business.
How has ISPC stock performed over the past year?
iSpecimen, Inc. returned -96.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does iSpecimen, Inc. do?
iSpecimen Inc. operates a proprietary online marketplace platform that connects life science researchers worldwide with hospitals, laboratories, and other organizations supplying human biospecimens, subjects, samples, and associated data.
About iSpecimen, Inc.
iSpecimen Inc. operates a proprietary online marketplace platform that connects life science researchers worldwide with hospitals, laboratories, and other organizations supplying human biospecimens, subjects, samples, and associated data. The iSpecimen Marketplace streamlines procurement by offering a diverse range of human biospecimens, including biofluids such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissues like fresh, fixed, cryopreserved samples, as well as formalin-fixed paraffin-embedded blocks, slides, and curls; and hematopoietic stem and immune cells from bone marrow, cord blood, whole blood, or isolated components like peripheral blood mononuclear cells. This platform addresses challenges in accessing high-quality, diverse specimens for research in diagnostics and therapeutics. iSpecimen Inc. serves biopharmaceutical companies, in vitro diagnostic firms, and government/academic institutions, facilitating faster biomedical discovery through efficient, compliant global networking. Founded in 2009 and headquartered in Woburn, Massachusetts, it plays a key role in the healthcare sector's diagnostics and research industry.
CEO Ms. Katharyn Field · 7 employees · United States · https://ispecimen.com